A record-breaking 70% of NYC Health + Hospitals’ primary care patients now have their Type 2 diabetes controlled, the New York City-based system said Nov. 19.
NYC Health + Hospitals defines Type 2 diabetes control as an A1C level below 8%. The 11-hospital system attributed the clinical accomplishment to two programs: The collaborative drug therapy management program and the treat to target program.
The first program embeds clinical pharmacists into primary care teams to help patients with diabetes, and the other has nurses lead hypertension and diabetes management.
Over the last year, the collaborative drug therapy management program served more than 9,000 patients and the treat to target program served nearly 24,000 patients, according to a news release from NYC Health + Hospitals.
Chateranie Shivram, a patient in the collaborative drug therapy management program, met monthly with pharmacist Carmen Chow, PharmD, at NYC Health + Hospitals/Jacobi. Fourteen months ago, Ms. Shivram had an A1C of 11.1% and six daily medications.
With Dr. Chow’s help, she now has an A1C of 6.7%, two daily medications and a reduced insulin dose by about 40%. Ms. Shivram is among 70% of NYC Health + Hospital primary care patients to have controlled diabetes.
“Congratulations to our care teams for attaining this incredible milestone,” NYC Health + Hospitals Senior Vice President of Ambulatory Care and Population Health Ted Long, MD, said in the release. “This is a culmination of many years of dedicated work at every level of our organization.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
